Eton Pharmaceuticals, Inc. (ETON) Debt / Equity
- 2025-12-31: Debt/Equity Ratio 1.17.
- 2024-12-31: Debt/Equity Ratio 1.22.
- 2023-12-31: Debt/Equity Ratio 0.35.
- 2023-09-30: Debt/Equity Ratio 0.34.
Complete source-backed debt/equity ratio history.
- Available history
- 2021-03-31 to 2025-12-31
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2025-12-31 | 1.17 |
| 2024-12-31 | 1.22 |
| 2023-12-31 | 0.35 |
| 2023-09-30 | 0.34 |
| 2023-06-30 | 0.36 |
| 2023-03-31 | 0.57 |
| 2022-12-31 | 0.49 |
| 2022-09-30 | 0.57 |
| 2022-06-30 | 0.48 |
| 2021-12-31 | 0.38 |
| 2021-09-30 | 0.42 |
| 2021-06-30 | 0.32 |
| 2021-03-31 | 0.3 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2025-12-31 | 1.17 |
| 2024-12-31 | 1.22 |
| 2023-12-31 | 0.35 |
| 2022-12-31 | 0.49 |
| 2021-12-31 | 0.38 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |